Brought to you by 
Prelude sells PersonalizeDx to Rosetta for $3.5mm in cash and stock
18 Sep 2020
Executive Summary
Rosetta Genomics Ltd. paid $2mm in cash and $1.5mm in stock (500k shares) to acquire private diagnostics company CynoGen Inc. (also known as PersonalizeDx) from Prelude Corp. As a form of payment, Rosetta will also provide Prelude with some assets and services.
Deal Industry
- In Vitro Diagnostics
- Laboratory Testing Services
- Services
-
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
- Urine-based Testing
-
Biotechnology
- Pharmacogenetics-Pharmacogenomics
Deal Status
- Final
Deal Type
-
Acquisition
- Acquisition of Private Biotech
- Full Acquisition
- Intra-Biotech Deal
- Payment Includes Cash
- Payment Includes Stock
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Prelude sells PersonalizeDx to Rosetta for $3.5mm in cash and stock
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice